Pyrimidine incorporated semicarbazones can be regarded as a newer class of anticonvulsants. These compounds possess the four essential pharmacophoric elements for good anticonvulsant activity. Most of the compounds display considerable anticonvulsant activity in both seizure models. (Ic) and (Id) of the most active compounds (Ia), (Ic) and (Id) do not show any sign of neurotoxicity. -(ALAM*, O.; MULLICK, P.; VERMA, S. P.; GILANI, S. J.; KHAN, S. A.; SIDDIQUI, N.; AHSAN, W.; Eur.

Thiadiazole Derivatives as Potential Anticonvulsant Agents. -A variety of thiadiazolyliminothiazolidinone derivatives (IX) and (XI) are synthesized, which show good potential for anticonvulsant activity and also neurotoxic effect. -(MULLICK*, P.; KHAN, S. A.; VERMA, S.; ALAM, O.; Bull. Korean Chem. Soc. 32 (2011) 3, 1011-1016, http://dx.

Liposomes, as the leading drug delivery system, have played a significant role in the formulation of anticancer drug to improve therapeutic effect. This system improves the pharmacokinetic and pharmacodynamic profiles of the therapeutic payload, promote controlled and sustained release of anticancer drugs, and exhibit very less systemic toxicity as compared to the free anticancer drug. The mechanism giving rise to therapeutic advantages of liposomes such as the ability of long-circulating liposomes to preferentially accumulate at disease sites such as tumors, site of infection, and site of inflammation. In the studies, liposomal anthracyclines have shown highly efficient drug encapsulation, resulting in significant anticancer activity with reduced cardiotoxicity. There are several methods for liposomes preparation based on lipid drug interaction and liposomes disposition mechanism including the incubation of rapid clearance of liposomes by controlling particle size and surface hydration. The liposomes are characterized with respect to physical, chemical, and biological parameters. This review discusses the recent advances in the preparation methods of liposome for the treatment of cancer.

In this study, easy and robust RP-HPLC method was developed and validated to determine acceptable residual limit of citalopram hydrobromide for cleaning procedures. The United States, Food and Drug Administration has mentioned that the acceptable limit for residues present in the equipment during processing or manufacturing should be based on logical criteria. In present study, acceptable residual limit for cleaning procedure of citalopram hydrobromide was calculated by using three approaches including therapeutic dose method, 10 ppm criteria and visual limit of inspection. The value by erapeutic dose approach was less among three calculated values hence, selected as acceptable residual limit (10.66 µg/25 cm2 ) for analytical method development and validation for the detection of this drug residues on the surfaces of manufacturing equipment. A RP-HPLC assay method was developed using C18 column and mobile phase containing mixture of methanol and ammonium acetate buffer (pH4.6) (70:30) with flow rate of 1.6 ml/min. System suitability parameters like theoretical plates and tailing factor were calculated for the validation of the developed method as per ICH Q2B guidelines. After analyzing recovery study data, it was found that stainless steel plate has minimum recovery (88.87%) and pre-analyzed tablet solution has maximum recovery (99.29%)

No abstract